Two Labs

Overview

Two Labs is the market-access and commercialization operating arm of Envision Pharma Group, which acquired Two Labs in November 2020 (~$280M at ~15x EBITDA). The acquired-brand stack includes legacy Two Labs (launch planning, channel strategy, field access), Riparian (government pricing, gross-to-net reporting, compliance, acquired Jul 2021), and MKO Global Partners (market-access consulting, acquired Feb 2018). Buyers searching Riparian or MKO should evaluate Two Labs as the current operating brand inside Envision Pharma Group.

Two Labs is not a top-of-house strategy boutique or a pure HEOR/policy shop. It is an execution-oriented operator built for small-to-mid biotech teams that need launch planning to convert into channel decisions, field workflows, government-pricing compliance, and adjacent medical-affairs support.

Market Access Capability Model

The framework below standardizes how Rx Almanac evaluates market-access-consulting capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Two Labs is evaluated as market-access and commercialization operating arm of Envision Pharma Group, which acquired Two Labs in November 2020 (~$280M at ~15x EBITDA).

Capability	Buyer should compare	Two Labs readout
Payer landscape and access strategy	Payer segmentation, formulary expectations, coverage barriers, benefit design, and access scenario planning.	Core. Market-access strategy and payer planning sit inside the legacy Two Labs and MKO capability set.
Pricing, contracting, and GTN strategy	WAC strategy, rebate design, contracting scenarios, GTN forecasting, channel economics, and net-price risk.	Core. Riparian division anchors gross-to-net reporting and pricing-support workstreams.
HEOR, value dossiers, and evidence planning	Budget impact, cost-effectiveness, AMCP dossier, evidence gaps, PRO endpoints, and value story.	Adjacent. Less of a top-of-house HEOR shop; ask for specific dossier or RWE examples.
Payer engagement and message testing	Ad boards, mock P&T, payer research, message testing, objection handling, and stakeholder mapping.	Confirm network reach in the RFP. Ask for recent payer-research case studies and primary-research panel composition.
Policy, IRA, Medicaid, and channel strategy	IRA, Medicaid, 340B, Medicare, specialty channel, distribution, and policy-risk implications.	Core. Riparian’s government-pricing compliance work, plus Two Labs’ specialty-channel and DSCSA capabilities, anchor the policy/channel lane.
Launch sequencing and execution support	Cross-functional launch planning, access playbooks, field tools, governance, and implementation support.	Core. 230+ product launches supported; built for emerging biopharma teams running lean launch infrastructure.

Buyer Fit

• Use-case fit: Small-to-mid biotech teams that need launch planning to convert into channel decisions, field access workflows, government-pricing compliance, and medical-affairs execution under one operator.
• Best-fit buyers: Emerging biopharma running their first or second launch; teams that prefer operator-oriented execution over strategy-slide consulting; manufacturers needing combined launch readiness plus Riparian government-pricing compliance.
• Less ideal fit: Large pharma seeking global market-access strategy at scale; buyers needing AMCP-grade HEOR or top-of-house policy/IRA consulting.
• Commercial fit: Custom/RFP; Riparian Cloud Platform has a SaaS-style ARR component for government-pricing compliance.
• Decision checks: Whether Two Labs or Riparian is leading each workstream, and how Envision sibling capabilities (medical communications, EnvisionOne Vantage analytics) plug into the engagement.

Differentiators

• Operator orientation: Built for execution rather than strategy slideware; small-to-mid biotech teams cite this as the differentiator vs. larger consultancies.
• Riparian government-pricing platform: Gross-to-net reporting, transparency, and compliance operations - a capability few peer firms house in-house.
• DSCSA and specialty-channel expertise: Anchored in 20+ years of specialty-channel operating work.
• Envision medical-affairs adjacency: Medical-affairs and scientific support strengthened materially after the 2020 Envision combination.
• Emerging-biopharma launch density: Claims involvement in launch of ~75% of products in the emerging biopharma segment.

RFP Questions

• Which workstreams are led by legacy Two Labs vs. Riparian vs. MKO, and who is the named senior operator on each?
• What Riparian Cloud Platform modules are included, and on what licensing terms?
• Which DSCSA, REMS, and specialty-channel implementations have been delivered for analogous assets in the past 24 months?
• How will Envision Pharma Group sibling capabilities (medical communications, EnvisionOne Vantage analytics) plug into the launch scope?
• What government-pricing, gross-to-net, and transparency reporting outputs are deliverable to compliance, finance, and trade teams?
• Which payer inputs are primary research, standing panels, claims/formulary data, or consultant judgment?
• How are change orders, pass-through costs, and Riparian platform fees governed?

Recent Activity

• 2026-04 - Envision Pharma Group named Nick Jones President of Envision Medical Communications and added senior Product/IT executives focused on AI-driven pharmaceutical services.
• 2025-03 - Howard Miller (former Two Labs CEO of record at Envision deal close) appointed Operating Executive at Halifax Group, signaling step-back from Two Labs operational CEO seat.
• 2025-02 - Envision launched the EnvisionOne Vantage analytics suite, bridging medical-affairs data and Two Labs’ launch planning.
• 2024-12 - Primary corporate HQ relocated from Powell, OH to Bridge Park in Dublin, OH.
• 2024-07 - Bill Shirey appointed President of Life Science Commercialization for Envision Pharma Group, with direct oversight of Two Labs and Riparian business units.